Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins

Diabetologia

Volumn 49, Issue 4, 2006, Pages 775-783

  Brown, B E ^a   Mahroof, F M ^a   Cook, N L ^a   Van Reyk, D M ^b   Davies, M J ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Aldehydes; Apolipoprotein B; Atherosclerosis; Cholesterol esters; Foam cells; Glycation; Hydrazines; Low density lipoproteins; Macrophages; Protein modification

Indexed keywords

ALDEHYDE DERIVATIVE; AMINO ACID; AMINOGUANIDINE; APOLIPOPROTEIN B; CARBONYL DERIVATIVE; CHOLESTEROL; CHOLESTEROL ESTER; GIRARD REACTION; GIRARD REAGENT P; GLYCOALDEHYDE; HYDRALAZINE; HYDRAZINE DERIVATIVE; LOW DENSITY LIPOPROTEIN; METFORMIN; METHYLGLYOXAL; REAGENT; SCAVENGER; STEROL; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL LEVEL; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG STRUCTURE; ELECTROPHORETIC MOBILITY; FEMALE; FOAM CELL; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID OXIDATION; LIPID STORAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN MODIFICATION;

ACETALDEHYDE; ANIMALS; CELL LINE; FOAM CELLS; GLYCOSYLATION; HYDRAZINES; LIPOPROTEINS, LDL; MICE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE;

EID: 33644832991     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0137-3     Document Type: Article

References (48)

1. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
2. World Health Organization (2002) Diabetes mellitus (Fact sheet No. 138). Geneva, WHO
3. Eaton JW, Dean RT (2000) Diabetes and atherosclerosis. In: Dean RT, Kelly DT (eds) Atherosclerosis. Oxford University Press, Oxford, pp 24-45
4. Jenkins AJ, Best JD, Klein RL, Lyons TJ (2004) Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev 20:349-368
5. Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis. N Engl J Med 295:369-416
6. Steinberg D (1997) Oxidative modification of LDL and atherogenesis. Circulation 95:1062-1071
7. Li AC, Glass CK (2002) The macrophage foam cell as a target for therapeutic intervention. Nat Med 8:1235-1242
8. Goldstein JL, Ho YK, Basu SK, Brown MS (1979) Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76:333-337
9. Lopes-Virella MF, Klein RL, Virella G (1996) Modification of lipoproteins in diabetes. Diabetes Metab Rev 12:69-90
10. Tomkin GH, Owens D (2001) Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 17:27-43
11. Lyons TJ, Jenkins AJ (1997) Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 8:174-180
12. Baynes JW, Thorpe SR (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28:1708-1716
13. Thorpe SR, Baynes JW (2003) Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25:275-281
14. Kawamura M, Heinecke JW, Chait A (1994) Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependant pathway. J Clin Invest 94:771-778
15. Chisolm GM, Steinburg D (2000) The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28:1815-1826
16. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications - a new perspective on an old paradigm. Diabetes 48:1-9
17. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581-592
18. Nagai R, Hayashi CM, Xia L, Takeya M, Horiuchi S (2002) Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J Biol Chem 277:48905-48912
19. Sakata N, Imanaga Y, Meng J et al (1999) Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 142:67-77
20. Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457-468
21. Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116
22. Odani H, Shinzato T, Matsumoto JU, Maeda K (1999) Increase in three α,β-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 256:89-93
23. Atkins TW, Thornally PJ (1989) Erythrocyte glyoxalase activity in genetically obese (ob/ob) and streptozotocin diabetic mice. Diabetes Res 11:125-129
24. Brown BE, Dean RT, Davies MJ (2005) Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden foam cells. Diabetologia 48:361-369
25. Khalifah RG, Baynes JW, Hudson BG (1999) Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257:251-258
26. Morgan PE, Sturgess AD, Davies MJ (2005) Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 52:2069-2079
27. Kritharides L, Jessup W, Gifford J, Dean RT (1993) A method for defining the stages of low-density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC. Anal Biochem 213:79-89
28. Knott HM, Brown BE, Davies MJ, Dean RT (2003) Glycation and glycoxidation of low-density lipoproteins by glucose and low molecular weight aldehydes: formation of modified and oxidised proteins. Eur J Biochem 270:3572-3582
29. Guyton JR, Klump KF (1994) Development of the atherosclerosis core region - chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb 14:1305-1314
30. March J (1992) Advanced organic chemistry. Wiley, New York
31. Rahbar S, Figarola JL (2003) Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 419:63-79
32. Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419:31-40
33. Brownlee M, Cerami A, Vlassara H (1988) Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 4:437-451
34. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N (1999) Reaction of metformin with dicarbonyl compounds: possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 58:1765-1773
35. UK Prospective Studies Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-883
36. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS (1999) Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48:198-202
37. Beisswenger P, Ruggiero-Lopez D (2003) Metformin inhibition of glycation processes. Diabetes Metab 29:895-103
38. Burcham PC, Fontaine FR, Kaminskas LM, Petersen DR, Pyke SM (2004) Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity. Mol Pharmacol 65:655-664
39. Burcham PC, Kaminskas LM, Fontaine FR, Petersen DR, Pyke SM (2002) Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology 181-182:229-236
40. Jinnouchi Y, Sano H, Nagai R et al (1998) Glycolaldehyde-modified low density lipoprotein leads to foam cells via the macrophage scavenger receptor. J Biochem (Tokyo) 123:1208-1217
41. McLellan AC, Thornalley PJ, Benn J, Sonksen PH (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 87:21-29
42. Proctor SD, Pabla CK, Mamo JCL (2000) Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis 1449:315-322
43. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J (2002) Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417:750-754
44. Williams KJ, Tabas I (1998) The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9:471-474
45. Karttunen P, Uusitupa M, Lamminsivu U (1983) The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. Int J Clin Pharmacol Ther Toxicol 21:31-36
46. Shepherd AM, Ludden TM, McNay JL, Lin MS (1980) Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther 28:804-811
47. Foote EF, Look ZM, Giles P, Keane WF, Halstenson CE (1995) The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. Am J Kidney Dis 25:420-425
48. Esterbauer H, Gebicki J, Puhl H, Jurgens G (1992) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13:341-390